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Table II. Factors associated with loss of primary patency on multivariate
analysis
Variable OR 95% CI
Discharge primary patency
Dialysis dependence 1.7 1.1-2.7
Previous ipsilateral lower extremity bypass 1.7 1.1-2.5
Tibial/pedal target 1.6 1.1-2.1
HR 95% CI
One-year primary patency
Female gender 1.2 1.0-1.5
Previous ipsilateral lower extremity bypass 1.4 1.1-1.8
Previous ipsilateral endovascular intervention 1.3 1.1-1.6
Tibial/pedal target 1.3 1.1-1.5
Graft crossing the knee 1.8 1.2-2.6
CI, Conﬁdence interval; HR, hazard ratio; OR, odds ratio.
JOURNAL OF VASCULAR SURGERY
538 Abstracts August 2014Indocyanine Green Angiographic Criteria Using Ingress and Ingress
Rate to Detect SVS Lower Extremity Threatened Limb Classiﬁcation
(WIfI) Grade 3 Ischemia
Jonathan D. Braun, MD, Pooja Rajguru, David G. Armstrong, MD, DPM,
PhD, Joseph L. Mills, MD. University of Arizona, Tucson, Ariz
Objective: The evaluation of patients presenting with foot wounds
and a spectrum of ischemia has grown more complex. Traditional means
of assessing whether blood ﬂow is sufﬁcient for healing are increasingly
limited by medial calcinosis, prior toe amputations, and open wounds. We
therefore sought to deﬁne the utility of indocyanine green angiography
(ICGA) as an alternative, objective perfusion assessment not subject to
such limitations.
Methods: ICGA uses a charge-coupled camera, a laser, and intrave-
nous contrast to assess skin perfusion. From January 2011 to December
2013, we performed ICGA within 5 days of 57 revascularization procedures
in patients with ischemia and tissue loss. Ankle-brachial indices (ABIs) and
toe pressures, when available, were compared with multiple, quantitative as-
pects of ICGA.
Results: A total of 46 patients underwent 57 revascularization proce-
dures (44 endovascular, 11 open, and 2 hybrid) for 48 lower limb wounds
(WIfI wound classes 1, 2, and 3 in 32.6%, 52.2%, and 15.2%, respectively);
85% were diabetic, and 24% were dialysis-dependent. The Society for
Vascular Surgery (SVS) ischemia classiﬁcation was not possible in one-third
of cases due to the inability to obtain standard measurements (65% incom-
pressible ABIs, 41% unable to measure toe pressures). We performed ICGA
in all patients and analyzed multiple parameters; ingress (increase in pixel
strength [PxS]) and ingress rate (slope of increase in PxS) both signiﬁcantly
correlated with available ABIs (P < .05). An ingress of 27.3 PxS and ingress
rate of 1.1 PxS/s corresponded to an ABI of 0.4, the cutoff for SVS WIfI
ischemia grade 3. After revascularization, 80% of patients had ingress
$27.3 PxS, 85% had ingress rates $1.1 PxS/s, and 100% of those with
compressible ABIs postoperatively had an ABI $0.4.
Conclusions: ICGA provides quantitative information about foot
perfusion even for patients in whom traditional noninvasive measurements
cannot be obtained. We believe this report is the ﬁrst to deﬁne speciﬁc
ICGA parameters for detecting severe ischemia (WIfI ischemia grade 3)
in predominantly diabetic patients with foot wounds and correlating them
with standard noninvasive studies. Further study is warranted to reﬁne the
use of this technology to appropriately select patients for revascularization
and predict wound healing.
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Intraoperative Completion Imaging Does Not Improve Primary
Patency for Lower Extremity Bypass: A Vascular Quality Initiative
Analysis
Owen P. Palmer, MD, Vincent L. Rowe, MD, Fred A. Weaver, MD, Karen
Woo, MD. University of Southern California, Los Angeles, Calif
Objective: This study was conducted to determine the inﬂuence of
intraoperative completion imaging (CI) for lower extremity vein bypass
(LEB) to a below-knee target on primary patency in the Vascular Quality
Initiative (VQI).
Methods: The VQI database was queried from January 2003 to
October 2013 for LEBs that were elective, had an indication of occlusive
disease, used a single-segment great saphenous vein conduit, and had a
below-knee target. LEBs with concomitant endovascular procedures were
excluded. CI was deﬁned as completion angiography and/or duplex. The
end points were primary patency at discharge and at 1 year.
Results: During the study period, 14,284 LEBs were performed, of
which 3151 satisﬁed the inclusion/exclusion criteria. A total of 1457
(46%) underwent CI: 287 duplex studies (20%), 1116 angiograms (77%) ,
and 54 both (3.7%). More patients in the CI group had a history of smoking
and bypass graft crossing the knee (Table I). Mean procedure time with CI
was 274 minutes vs 244 minutes without CI (P < .0001). CI did not in-
ﬂuence primary patency at discharge (CI: 93.2% vs no CI: 93.8%; P ¼ .52).
Discharge primary patency was 95.1% for completion duplex vs 92.8% for
completion angiogram (P ¼ .17). The 1-year primary patency was 63% in
the CI group vs 68% in the no CI group (P ¼ .051). The 1-year primary
patency was 60% for completion duplex vs 65% for completion angiogram
(P ¼ .61). On univariate and multivariate analysis, CI did not signiﬁcantly
inﬂuence primary patency, although multiple other factors were associated
with a loss of primary patency (Table II).
Conclusions: Procedures with intraoperative CI require a mean proce-
dure time of 30 minutes more than procedures without CI. However, CI is
not associated with improved discharge or 1-year primary patency of elective
LEB grafts with a below-knee target artery performed for occlusive disease.Table I. Patient characteristics
Completion imagingVariables Y Pes (n ¼ 1457) No (n ¼ 1694)Age, mean year 66.6 67.2 .12
Male, No. (%) 1031 (71) 1165 (69) .25
White race, No. (%) 1238 (85) 1393 (82) .06
Hypertension, No. (%) 1294 (89) 1489 (88) .57
Diabetes, No. (%) 742 (51) 874 (52) .65
End-stage renal disease, No. (%) 97 (6.7) 108 (6.4) .77
Coronary artery disease, No. (%) 458 (31) 478 (28) .053
History of smoking, No. (%) 1217 (84) 1356 (80) .02
Previous ipsilateral lower extremity
Bypass, No. (%) 154 (11) 185 (11) .73
Endovascular intervention, No. (%) 336 (23) 423 (25) .2Tibial/pedal target artery, No. (%) 812 (56) 929 (55) .67
Graft crossing the knee, No. (%) 1363 (94) 1536 (91) .005Author Disclosures: O. P. Palmer: None; V. L. Rowe: None; F. A.
Weaver: None; K. Woo: None.
Presentation of Symptomatic PAD in Patients with Chronic HIV
Infection
Shant M. Vartanian, MD, Sukgu M. Han, MD, Bian Wu, MD, Warren J.
Gasper, MD, Christopher D. Owens, MD, Michael S. Conte, MD.
University of California, San Francisco, San Francisco, Calif
Objective: The enhanced longevity of patients living with chronic
HIV infection has resulted in an increased burden of chronic diseases. There
is growing evidence that HIV-infected patients are at a higher-than-ex-
pected risk of coronary artery disease by 1.5 to 2 times. The signiﬁcance
of chronic HIV infection in the peripheral vasculature is largely unknown.
Methods: This was a retrospective analysis of patients with HIV infec-
tion referred for initial consultation to vascular surgery clinics at three teach-
ing hospitals over a 3-year period. Records were reviewed for clinical
presentation, comorbid conditions, duration of HIV infection, antiretroviral
treatment history, and biochemical proﬁle. Imaging studies were reviewed
to localize the distribution of atherosclerosis.
Results: Twenty-seven patients (25 men [93%]) with HIV infection
were referred for symptoms related to peripheral arterial disease (21 of 27
[78%]) or extracranial cerebrovascular disease (6 of 27 [22%]). The average
agewas 59.8 years (range, 35-74 years). Traditional atherosclerosis risk factors
were present in varying amounts, including hypertension (22 of 27 [81%]),
diabetes (8 of 27 [30%]), family history (6 of 27 [22%]), and active smoking
(6 of 27 [22%]). The average duration of HIV infection was 18 years (range,
11-30 years). Chronic infection was well controlled (mean current CD4+ cell
count, 554; viral load<75 copies/mL in 25 of 27 [93%]). Twenty-six patients
were being actively treated with highly active antiretroviral therapy (mean
duration, 12.5 years), and 23of the 26 regimens included a nucleoside/nucle-
otide reverse transcriptase inhibitor. The distribution of atheromawas diffuse,
with the femoropopliteal segment most frequently involved (15 of 27 [56%]),
followed by aortoiliac disease (12 of 27 [44%’), infrageniculate disease (9 of 27
[33%]), and carotid bulb disease (6 of 27 [22%]).
Conclusions: Patients with chronic HIV infection can present with
clinically signiﬁcant PAD at a young age. The distribution of disease is
